We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+20.21%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$2.06B
AUM Growth
-$300M
Cap. Flow
-$581M
Cap. Flow %
-28.26%
Top 10 Hldgs %
86.31%
Holding
41
New
11
Increased
3
Reduced
4
Closed
8
Avg Time Held Equity + Options
4.9 quarters
Top 10 Avg Time Held Equity + Options
4.3 quarters
Top 20 Avg Time Held Equity + Options
4.1 quarters
Avg Time Held Equity only
5.3 quarters
Top 10 Avg Time Held Equity only
4.3 quarters
Top 20 Avg Time Held Equity only
4.1 quarters

Top Buys

Rank Stock Value
1
TRAX icon
First Tracks Biotherapeutics
TRAX
+$59.3M
2
FULC icon
Fulcrum Therapeutics
FULC
+$39.8M
3
CGON icon
CG Oncology
CGON
+$25.6M
4
LEGN icon
Legend Biotech
LEGN
+$21.6M
5
STOK icon
Stoke Therapeutics
STOK
+$20.4M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$323M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$238M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$156M
4
XNCR icon
Xencor
XNCR
+$26.3M
5
RLAY icon
Relay Therapeutics
RLAY
+$17.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.95%
2 Miscellaneous 1.95%
3 Financials 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
NRIX icon
26
Nurix Therapeutics
NRIX
$2.3B
$6.55M 0.32%
+270,000
New +$4.6M
2026 Q2
0 quarters
ERAS icon
27
Erasca
ERAS
$5.17B
$6.05M 0.29%
330,000
-570,000
-63% -$8.15M
2026 Q1
1 quarter
ELOX icon
28
Eloxx Pharmaceuticals
ELOX
$43.6M
$5.55M 0.27%
+400,000
New +$5.1M
2026 Q2
0 quarters
AARD icon
29
Aardvark Therapeutics
AARD
$88.4M
$2.28M 0.11%
+396,194
New +$1.85M
2026 Q2
0 quarters
HLXC icon
30
Helix Acquisition Corp III
HLXC
$231M
$2.13M 0.1%
200,000
– –
2026 Q1
1 quarter
MREO icon
31
Mereo BioPharma
MREO
$51.1M
$318K 0.02%
1,000,000
-12,368,855
-93% -$3.71M
2025 Q4
2 quarters
SRZNW icon
32
DELISTED
Surrozen Inc Warrant
SRZNW
$115K 0.01%
4,444
– –
2021 Q2
20 quarters
AARD icon
33
CALL
Aardvark Therapeutics
AARD
$88.4M
$84.7K ﹤0.01%
+14,700
New +$68.7K
2026 Q2
0 quarters
CNTA
34
CALL
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-410,800
Closed -$16.3M –
CNTA
35
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-6,000,000
Closed -$238M –
CRNX icon
36
DELISTED
Crinetics Pharmaceuticals
CRNX
– –
-4,288,120
Closed -$156M –
IBIO icon
37
iBio
IBIO
$50.3M
– –
-1,583,000
Closed -$3.01M –
JAZZ icon
38
Jazz Pharmaceuticals
JAZZ
$13.7B
– –
-1,706,469
Closed -$323M –
PRLD icon
39
Prelude Therapeutics
PRLD
$284M
– –
-947,049
Closed -$3.24M –
REPL icon
40
Replimune Group
REPL
$1.14B
– –
-1,000,000
Closed -$7.65M –
XNCR icon
41
Xencor
XNCR
$1.75B
– –
-2,183,000
Closed -$26.3M –
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2026 Portfolio in Review

As of Q2 2026, EcoR1 Capital held 41 positions worth $2.06B, down 13% from $2.36B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

EcoR1 Capital withdrew a net $581M in Q2 2026, closing 8 positions and reducing 4 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $323M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, EcoR1 Capital opened a new position in First Tracks Biotherapeutics worth $63.9M.

  • EcoR1 Capital's largest Q2 2026 buy was First Tracks Biotherapeutics: 3,174,519 shares worth $63.9M.
  • EcoR1 Capital added most to CG Oncology in Q2 2026, an estimated $25.6M increase.
  • EcoR1 Capital's biggest Q2 2026 reduction was Relay Therapeutics, cutting an estimated $17.5M.
  • EcoR1 Capital fully exited Jazz Pharmaceuticals in Q2 2026, selling an estimated $323M.
  • EcoR1 Capital's ten largest holdings make up 86% of its $2.06B portfolio in Q2 2026.
  • EcoR1 Capital opened 11 new positions and closed 8 in Q2 2026.
  • EcoR1 Capital's portfolio value fell 13% quarter-over-quarter to $2.06B.

Based on EcoR1 Capital's 13F filing for Q2 2026, filed 14 Aug 2026.